Skip to main content
. 2022 Aug 29;22:933. doi: 10.1186/s12885-022-10032-5

Fig. 1.

Fig. 1

Notch signaling mutation activates immune responses in CRC. A The expressions of checkpoint and effector molecules in different groups of CRC patients in TCGA (P values were determined by the One-way ANOVA test. **p < 0.01, ***p < 0.001). B Proportions of patients with different CMS in mutation and WT groups. C Proportions of Notch mutation and WT patients in different CMS groups